Athena Athena

X
[{"orgOrder":0,"company":"Elevian","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elevian Announces $15 Million Equity Financing","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"Elevian","sponsor":"Prime Movers Lab","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Elevian Raises $40 Million Series A to Advance Treatments for Stroke Recovery and Age-Related Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Elevian

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The funding will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for GDF11, for lead indication of stroke recovery.

            Lead Product(s): rGDF11

            Therapeutic Area: Neurology Product Name: rGDF11

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Prime Movers Lab

            Deal Size: $40.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from the equity financing will enable Elevian to advance recombinant GDF11 (rGDF11) toward the clinic to treat stroke and other age-related diseases.

            Lead Product(s): rGDF11

            Therapeutic Area: Neurology Product Name: rGDF11

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Prime Movers Lab

            Deal Size: $15.0 million Upfront Cash: Undisclosed

            Deal Type: Financing November 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY